Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 2INTERVENTIONAL

Rupatadine in Patients With Ulcerative Colitis

Clinical Study to Evaluate Safety and Efficacy of Rupatadine in Patients With Ulcerative Colitis.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Ulcerative colitis (UC) is a chronic inflammatory condition that primarily targets the large intestine. Although substantial progress has been made in treatment modalities-especially with the development of immunomodulatory drugs and biologic therapies-managing UC continues to present significant challenges. At present, there is no definitive cure, and current treatment strategies are largely focused on controlling inflammation, relieving symptoms, and halting disease progression

Who May Be Eligible (Plain English)

Who May Qualify: - Age ≥ 18 years - Both male and female will be included - Mild and moderate UC patients are already diagnosed and confirmed by endoscope and histopathology. Who Should NOT Join This Trial: - Breast feeding or pregnancy. - Colorectal cancer patients. - Patients with severe UC. - Patients taking rectal or systemic steroids. - Patients taking immunosuppressives or biological therapies. - Addiction to alcohol and / or drugs. - Known allergy to the studied medications. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion criteria: * Age ≥ 18 years * Both male and female will be included * Mild and moderate UC patients are already diagnosed and confirmed by endoscope and histopathology. Exclusion criteria: * Breast feeding or pregnancy. * Colorectal cancer patients. * Patients with severe UC. * Patients taking rectal or systemic steroids. * Patients taking immunosuppressives or biological therapies. * Addiction to alcohol and / or drugs. * Known allergy to the studied medications.

Treatments Being Tested

DRUG

Mesalamine

Mesalamine or 5-amino salicylic acid (5-ASA), plays a crucial role in the treatment of ulcerative colitis (UC). It is the first-line therapy for mild to moderate cases of UC and is considered a cornerstone in its management.

DRUG

Rupatadine

Rupatadine, a dual histamine H1 receptor and platelet-activating factor (PAF) receptor antagonist, has shown promising anti-inflammatory effects beyond its conventional use in allergic conditions

Locations (1)

Alexandria University
Alexandria, Egypt